FGEN vs. ELYM, CLSD, OPTN, BRNS, RNAC, CLRB, IMUX, VACC, ANIX, and CTMX
Should you be buying FibroGen stock or one of its competitors? The main competitors of FibroGen include Eliem Therapeutics (ELYM), Clearside Biomedical (CLSD), OptiNose (OPTN), Barinthus Biotherapeutics (BRNS), Cartesian Therapeutics (RNAC), Cellectar Biosciences (CLRB), Immunic (IMUX), Vaccitech (VACC), Anixa Biosciences (ANIX), and CytomX Therapeutics (CTMX). These companies are all part of the "pharmaceutical preparations" industry.
FibroGen (NASDAQ:FGEN) and Eliem Therapeutics (NASDAQ:ELYM) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, community ranking, institutional ownership, risk, media sentiment, profitability, valuation, dividends and earnings.
FibroGen has a beta of 0.7, indicating that its stock price is 30% less volatile than the S&P 500. Comparatively, Eliem Therapeutics has a beta of 0.51, indicating that its stock price is 49% less volatile than the S&P 500.
Eliem Therapeutics has lower revenue, but higher earnings than FibroGen. Eliem Therapeutics is trading at a lower price-to-earnings ratio than FibroGen, indicating that it is currently the more affordable of the two stocks.
Eliem Therapeutics has a net margin of 0.00% compared to FibroGen's net margin of -192.37%. FibroGen's return on equity of 0.00% beat Eliem Therapeutics' return on equity.
72.7% of FibroGen shares are owned by institutional investors. Comparatively, 69.8% of Eliem Therapeutics shares are owned by institutional investors. 2.4% of FibroGen shares are owned by company insiders. Comparatively, 4.7% of Eliem Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
FibroGen received 334 more outperform votes than Eliem Therapeutics when rated by MarketBeat users. Likewise, 62.36% of users gave FibroGen an outperform vote while only 56.25% of users gave Eliem Therapeutics an outperform vote.
FibroGen presently has a consensus price target of $17.00, suggesting a potential upside of 1,534.62%. Given FibroGen's higher probable upside, analysts plainly believe FibroGen is more favorable than Eliem Therapeutics.
In the previous week, Eliem Therapeutics had 4 more articles in the media than FibroGen. MarketBeat recorded 6 mentions for Eliem Therapeutics and 2 mentions for FibroGen. Eliem Therapeutics' average media sentiment score of 0.86 beat FibroGen's score of -0.87 indicating that Eliem Therapeutics is being referred to more favorably in the news media.
Summary
FibroGen beats Eliem Therapeutics on 8 of the 15 factors compared between the two stocks.
Get FibroGen News Delivered to You Automatically
Sign up to receive the latest news and ratings for FGEN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding FGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
FibroGen Competitors List
Related Companies and Tools
